Eton Financial Statements From 2010 to 2025

ETON Stock  USD 14.68  0.61  3.99%   
Eton Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Eton Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Eton Pharmaceuticals financial statements helps investors assess Eton Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Eton Pharmaceuticals' valuation are summarized below:
Gross Profit
14.3 M
Profit Margin
(0.21)
Market Capitalization
236.9 M
Enterprise Value Revenue
11.1904
Revenue
31.4 M
We have found one hundred twenty available fundamental signals for Eton Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Eton Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 82.9 M. Also, Enterprise Value is likely to grow to about 71.5 M

Eton Pharmaceuticals Total Revenue

38.21 Million

Check Eton Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eton Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 596.8 K or Selling General Administrative of 12.9 M, as well as many indicators such as Price To Sales Ratio of 8.4, Dividend Yield of 0.0214 or PTB Ratio of 14.83. Eton financial statements analysis is a perfect complement when working with Eton Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Eton Pharmaceuticals Correlation against competitors.
To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.

Eton Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets26.6 M36.5 M20.4 M
Slightly volatile
Other Current Liabilities10.9 M10.4 M2.5 M
Slightly volatile
Total Current Liabilities19.6 M18.7 MM
Slightly volatile
Total Stockholder Equity12.7 M13.9 M13.9 M
Pretty Stable
Property Plant And Equipment Net128.2 K135 K306.1 K
Pretty Stable
Accounts Payable1.6 M2.1 M1.1 M
Slightly volatile
Cash19.7 M24.6 M16.4 M
Slightly volatile
Non Current Assets Total2.9 M5.6 M1.8 M
Slightly volatile
Non Currrent Assets Other10.3 K10.8 K29.7 K
Slightly volatile
Other Assets10.3 K10.8 K41.7 K
Very volatile
Cash And Short Term Investments19.7 M24.6 M16.4 M
Slightly volatile
Common Stock Total Equity20 K28.8 K14.5 K
Slightly volatile
Common Stock Shares Outstanding21.6 M29.5 M18.9 M
Slightly volatile
Liabilities And Stockholders Equity26.6 M36.5 M20.4 M
Slightly volatile
Non Current Liabilities Total24 K25.3 K1.7 M
Slightly volatile
Capital Surpluse82 M133.6 M52.1 M
Slightly volatile
Other Current Assets2.5 M1.3 M1.3 M
Slightly volatile
Other Stockholder Equity97.9 M137.4 M62.7 M
Slightly volatile
Total Liabilities19.6 M18.7 M6.6 M
Slightly volatile
Property Plant And Equipment Gross479.5 K490.5 K374.9 K
Slightly volatile
Total Current Assets23.7 M30.9 M18.7 M
Slightly volatile
Net Working Capital13.2 M9.5 M14.1 M
Pretty Stable
Common Stock22.3 K29.9 K14.8 K
Slightly volatile
Property Plant Equipment61.6 K64.8 K280.9 K
Pretty Stable
Capital Stock24.9 K29.9 K20.9 K
Slightly volatile
Short and Long Term Debt Total6.7 M6.2 M5.3 M
Slightly volatile
Net Receivables2.5 M3.9 M1.4 M
Slightly volatile
Long Term Debt TotalM6.2 MM
Slightly volatile
Capital Lease Obligations24 K25.3 K30.1 K
Slightly volatile
Non Current Liabilities Other167.2 K123 K70.7 K
Slightly volatile

Eton Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative12.9 M21.8 M9.4 M
Slightly volatile
Research Development5.8 MM6.3 M
Very volatile
Total Operating Expenses20.8 M25.6 M15.9 M
Slightly volatile
Interest Income244.8 K323.1 K215.6 K
Slightly volatile
Depreciation And Amortization783.6 KM412.4 K
Slightly volatile
Reconciled Depreciation788 KM414.1 K
Slightly volatile
Selling And Marketing Expenses53.6 K60.3 K65.7 K
Slightly volatile

Eton Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock214.6 K225.9 K12.3 M
Slightly volatile
Depreciation678.5 KM385.5 K
Slightly volatile
Capital Expenditures1.4 M891.2 K802.7 K
Slightly volatile
End Period Cash Flow19.7 M24.6 M16.4 M
Slightly volatile
Change To Netincome3.7 M4.9 M3.2 M
Slightly volatile
Stock Based Compensation3.1 M3.6 M2.4 M
Slightly volatile
Begin Period Cash Flow13.9 M14.7 M14.9 M
Slightly volatile
Other Non Cash Items100 K105.3 K1.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.48.8416359
Very volatile
Dividend Yield0.02140.0240.0262
Slightly volatile
PTB Ratio14.8314.11999.0154
Pretty Stable
Days Sales Outstanding47.6550.1593157
Slightly volatile
Book Value Per Share1.220.94330.9364
Very volatile
Stock Based Compensation To Revenue0.07710.08115.3968
Very volatile
Capex To Depreciation0.02160.02272.9657
Slightly volatile
PB Ratio14.8314.11999.0154
Pretty Stable
EV To Sales8.048.4615331
Very volatile
Inventory Turnover0.971.02422.686
Slightly volatile
Days Of Inventory On Hand437356349
Very volatile
Payables Turnover3.933.74371.2469
Slightly volatile
Sales General And Administrative To Revenue0.550.583225.5748
Very volatile
Research And Ddevelopement To Revenue0.07930.083430.1795
Very volatile
Capex To Revenue6.0E-47.0E-41.3023
Slightly volatile
Cash Per Share0.550.57680.9417
Very volatile
Days Payables Outstanding92.6297.49718.3 K
Slightly volatile
Intangibles To Total Assets0.480.45820.116
Slightly volatile
Net Debt To EBITDA7.445.71015.9225
Slightly volatile
Current Ratio1.952.056510.9857
Slightly volatile
Receivables Turnover4.657.27683.6097
Slightly volatile
Shareholders Equity Per Share1.220.94330.9364
Very volatile
Debt To Equity0.00420.00440.3758
Slightly volatile
Capex Per Share0.0010.0010.0297
Slightly volatile
Revenue Per Share1.581.50650.4108
Slightly volatile
Debt To Assets0.00130.00140.2262
Slightly volatile
Operating Cycle592407512
Very volatile
Price Book Value Ratio14.8314.11999.0154
Pretty Stable
Days Of Payables Outstanding92.6297.49718.3 K
Slightly volatile
Ebt Per Ebit0.871.46631.0357
Very volatile
Company Equity Multiplier3.273.11621.5719
Slightly volatile
Long Term Debt To Capitalization0.00480.0050.2404
Slightly volatile
Total Debt To Capitalization0.00410.00440.2629
Slightly volatile
Debt Equity Ratio0.00420.00440.3758
Slightly volatile
Quick Ratio1.231.292910.844
Slightly volatile
Net Income Per E B T0.931.00391.048
Slightly volatile
Cash Ratio0.710.748810.3844
Slightly volatile
Days Of Inventory Outstanding437356349
Very volatile
Days Of Sales Outstanding47.6550.1593157
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.120.97321.0278
Very volatile
Price To Book Ratio14.8314.11999.0154
Pretty Stable
Fixed Asset Turnover19618748.9103
Slightly volatile
Debt Ratio0.00130.00140.2262
Slightly volatile
Price Sales Ratio8.48.8416359
Very volatile
Asset Turnover0.430.51250.2592
Slightly volatile
Price Fair Value14.8314.11999.0154
Pretty Stable

Eton Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap82.9 M63.8 M98.1 M
Slightly volatile
Enterprise Value71.5 M55 M85.4 M
Slightly volatile

Eton Fundamental Market Drivers

Forward Price Earnings19.1571
Cash And Short Term Investments21.4 M

Eton Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Eton Pharmaceuticals Financial Statements

Eton Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Eton Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-119.7 K-125.7 K
Total Revenue36.4 M38.2 M
Cost Of Revenue12.2 M12.8 M
Stock Based Compensation To Revenue 0.08  0.08 
Sales General And Administrative To Revenue 0.58  0.55 
Research And Ddevelopement To Revenue 0.08  0.08 
Revenue Per Share 1.51  1.58 
Ebit Per Revenue(0.07)(0.07)

Pair Trading with Eton Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eton Stock

  0.65DMAC DiaMedica TherapeuticsPairCorr

Moving against Eton Stock

  0.71DSGN Design TherapeuticsPairCorr
  0.7VINC Vincerx PharmaPairCorr
  0.68VKTX Viking TherapeuticsPairCorr
  0.49DYAI Dyadic International Earnings Call This WeekPairCorr
  0.48VERA Vera TherapeuticsPairCorr
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Eton Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eton Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eton Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eton Pharmaceuticals Stock:
Check out the analysis of Eton Pharmaceuticals Correlation against competitors.
To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Earnings Share
(0.26)
Revenue Per Share
1.219
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.12)
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.